Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood

Gary J Weil, Kurt C Curtis, Lawrence Fakoli, Kerstin Fischer, Lincoln Gankpala, Patrick J Lammie, Andrew C Majewski, Sonia Pelletreau, Kimberly Y Won, Fatorma K Bolay, Peter U Fischer, Gary J Weil, Kurt C Curtis, Lawrence Fakoli, Kerstin Fischer, Lincoln Gankpala, Patrick J Lammie, Andrew C Majewski, Sonia Pelletreau, Kimberly Y Won, Fatorma K Bolay, Peter U Fischer

Abstract

Global Program to Eliminate Lymphatic Filariasis (GPELF) guidelines call for using filarial antigen testing to identify endemic areas that require mass drug administration (MDA) and for post-MDA surveillance. We compared a new filarial antigen test (the Alere Filariasis Test Strip) with the reference BinaxNOW Filariasis card test that has been used by the GPELF for more than 10 years. Laboratory testing of 227 archived serum or plasma samples showed that the two tests had similar high rates of sensitivity and specificity and > 99% agreement. However, the test strip detected 26.5% more people with filarial antigenemia (124/503 versus 98/503) and had better test result stability than the card test in a field study conducted in a filariasis-endemic area in Liberia. Based on its increased sensitivity and other practical advantages, we believe that the test strip represents a major step forward that will be welcomed by the GPELF and the filariasis research community.

Conflict of interest statement

Disclosure: The filarial antigen tests evaluated in this study use reagents licensed from Barnes-Jewish Hospital, an affiliation of G.J.W. All royalties from sales of these tests are donated to the Barnes-Jewish Hospital Foundation, a registered not-for-profit organization (http://www.barnesjewish.org/groups/default).

Figures

Figure 1.
Figure 1.
Left shows a strongly positive Alere Filariasis Test Strip (the lower line is the T or test line; score of 2+). Right shows a weakly positive BinaxNOW Filariasis card test (score of 1+). The tests were performed with the same blood sample, and the photograph was taken 10 minutes after starting the tests.

References

    1. WHO . The Global Programme to Eliminate Lymphatic Filariasis: Progress Report 2000–2009 and Strategic Plan 2010–2020. Geneva: World Health Organization; 2011. pp. 1–78.
    1. WHO Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiol Rec. 2012;87:346–356.
    1. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ. 1997;75:491–503.
    1. Michael E, Bundy DA, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996;112:409–428.
    1. Weil GJ, Ramzy RM. Diagnostic tools for filariasis elimination programs. Trends Parasitol. 2007;23:78–82.
    1. More SJ, Copeman DB. A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis. Trop Med Parasitol. 1990;41:403–406.
    1. Weil GJ, Jain DC, Santhanam S, Malhotra A, Kumar H, Sethumadhavan KV, Liftis F, Ghosh TK. A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenemia in bancroftian filariasis. J Infect Dis. 1987;156:350–355.
    1. Forsyth KP, Spark R, Kazura J, Brown GV, Peters P, Heywood P, Dissanayake S, Mitchell GF. A monoclonal antibody-based immunoradiometric assay for detection of circulating antigen in bancroftian filariasis. J Immunol. 1985;134:1172–1177.
    1. Gass K, Beau de Rochars MV, Boakye D, Bradley M, Fischer PU, Gyapong J, Itoh M, Ituaso-Conway N, Joseph H, Kyelem D, Laney SJ, Legrand AM, Liyanage TS, Melrose W, Mohammed K, Pilotte N, Ottesen EA, Plichart C, Ramaiah K, Rao RU, Talbot J, Weil GJ, Williams SA, Won KY, Lammie P. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis. 2012;6:e1479.
    1. WHO . Lymphatic Filariasis Transmission Assessment Surveys. Geneva: World Health Organization; 2011. pp. 1–100.
    1. Simonsen PE, Magesa SM. Observations on false positive reactions in the rapid NOW filariasis card test. Trop Med Int Health. 2004;9:1200–1202.
    1. Krolewiecki AJ, Ramanathan R, Fink V, McAuliffe I, Cajal SP, Won K, Juarez M, Di Paolo A, Tapia L, Acosta N, Lee R, Lammie P, Abraham D, Nutman TB. Improved diagnosis of Strongyloides stercoralis using recombinant antigen-based serologies in a community-wide study in northern Argentina. Clin Vaccine Immunol. 2010;17:1624–1630.
    1. Weil GJ, Malane MS, Powers KG, Blair LS. Monoclonal antibodies to parasite antigens found in the serum of Dirofilaria immitis-infected dogs. J Immunol. 1985;134:1185–1191.
    1. Supali T, Wibowo H, Ruckert P, Fischer K, Ismid IS, Purnomo, Djuardi Y, Fischer P. High prevalence of Brugia timori infection in the highland of Alor Island, Indonesia. Am J Trop Med Hyg. 2002;66:560–565.
    1. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet. 2006;367:992–999.
    1. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, King CL, Kazura JW, Bockarie MJ. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis. 2008;2:e344.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅